Teva scores Copaxone patent victory in Europe

10-12-2015

Teva scores Copaxone patent victory in Europe

Photo: Courtesy of Teva

Teva has been handed a victory after a patent covering its multiple sclerosis drug Copaxone (glatiramer acetate) was declared valid until 2030.


Teva, Mylan, Sandoz, Copaxone, European Patent Office, Securities and Exchange Commission, patent

LSIPR